Skip to main content
    E

    Enlivex Therapeutics Ltd (ENLV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.22
    +0.01 (+3.99%)

    Market Cap: $4.43M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(17/28)
    Avg Surprise
    -37.89%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Sep 4
    		$-1.20$-0.31-287.10%Miss+0.0%
    Mar 26
    Reported Jun 26
    		$-0.15$-0.02-650.00%Miss+93.3%
    Dec 25
    Reported Mar 25
    		$-1.41$-0.45-213.33%Miss-513.0%
    Sep 25
    Reported Nov 14
    		$-1.35$-1.80+25.00%Beat+25.0%
    Jun 25
    Reported Aug 29
    		$-1.20$-2.40+50.00%Beat+50.0%
    Mar 25
    Reported May 30
    		$-2.25$-2.40+6.25%Beat+31.8%
    Dec 24
    Reported Feb 26
    		$-0.23$-0.16-43.75%Miss+96.8%
    Sep 24
    Reported Nov 29
    		$-1.80$-2.40+25.00%Beat+62.5%
    Jun 24
    Reported Aug 30
    		$-2.40$-1.20-100.00%Miss-500.0%
    Mar 24
    Reported Jun 14
    		$-3.30$-3.75+12.00%Beat+43.6%
    Dec 23
    Reported Mar 29
    		$-7.20$-4.20-71.43%Miss-23.1%
    Sep 23
    Reported Nov 9
    		$-4.80$-4.80+0.00%Beat-3.2%
    Jun 23
    Reported Sep 1
    		$-0.40$-0.46+13.04%Beat+95.1%
    Mar 23
    Reported Apr 4
    		$-5.85$-6.00+2.50%Beat+13.3%
    Dec 22
    Reported Mar 31
    		$-5.85$-5.70-2.63%Miss-105.3%
    Sep 22
    Reported Dec 5
    		$-4.65$-4.35-6.90%Miss-82.4%
    Jun 22
    Reported Aug 22
    		$-8.10$-6.75-20.00%Miss-184.2%
    Mar 22
    Reported Apr 29
    		$-6.75$-6.15-9.76%Miss-2600.0%
    Sep 21
    Reported Nov 22
    		$-2.85$-3.15+9.52%Beat-18.8%
    Jun 21
    Reported Aug 9
    		$-2.55$-3.90+34.62%Beat+26.1%
    Mar 21
    Reported Apr 30
    		$-2.85$-3.15+9.52%Beat-171.4%
    Dec 20
    Reported Feb 26
    		$-0.25$-0.24-4.17%Miss+0.0%
    Sep 20
    Reported Oct 30
    		$-2.40$-2.70+11.11%Beat-900.0%
    Jun 20
    Reported Aug 14
    		$-3.45$-3.60+4.17%Beat-2056.3%
    Mar 20
    Reported Apr 30
    		$-1.05N/A+70.83%Beat-556.3%
    Dec 19
    Reported Feb 21
    		$-0.25$-0.25+0.00%Beat-56.3%
    Sep 19
    Reported Nov 14
    		$-0.24N/AN/ABeat-100.0%
    Jun 19
    Reported Jul 26
    		$-0.16N/AN/ABeat+68.0%
    Mar 19
    Reported Apr 30
    		$-0.16N/AN/ABeat+93.2%
    Dec 18
    Reported Mar 27
    		$-0.16$0.00N/AMiss+0.0%
    Sep 18
    Reported Dec 31
    		$-0.12$0.00N/AMiss+95.3%
    Jun 18
    Reported Jul 26
    		$-0.50$0.00N/AMiss+87.5%
    Mar 18
    Reported Apr 6
    		$-2.34$0.00N/AMiss+63.4%
    Dec 17
    Reported Feb 23
    		$-0.16N/AN/ABeat+97.9%
    Sep 17
    Reported Nov 2
    		$-2.56$0.00N/ABeat-
    Jun 17
    Reported Aug 4
    		$-4.00$0.00N/ABeat-
    Mar 17
    Reported May 26
    		$-6.40$-11.60+44.83%Beat-
    Dec 16
    Reported Feb 24
    		$-7.60$-10.80+29.63%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.05EV/EBITDAN/A
    Price/FCF-0.27xFCF Yield-365.59%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE162.90%ROIC-0.29%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio119.39xQuick Ratio119.39x
    Trading Statistics
    Beta1.41Avg Volume2.34M
    52-Week High$19.8052-Week Low$0.22

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.28
    SMA 20$0.44
    SMA 50$1.01
    SMA 200$9.38
    EMA 10$0.30
    EMA 20$0.47
    EMA 50$1.54
    EMA 200$7.43

    MACD

    Line: -0.28Signal: -0.33Hist: 0.04

    ADX

    ADX: 48.8+DI: 8.1-DI: 24.0

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$0.40

    Bollinger Bands

    Upper Band$0.80
    Lower Band$0.08
    %B Position16534%(Upper)
    Band Width0.21

    RSI (14-Day)

    Oversold
    12.4

    Momentum Oscillators

    Stoch %K1.8
    Stoch %D2.9
    Williams %R-96.4
    ROC (10d)-47.0%
    Momentum-0.20
    CCI (20d)-97.8
    MFI (14d)74.9

    Volatility Measures

    ATR (14d)$0.14(62.7%)
    StdDev (20d)0.18
    Hist Vol108.6%(High)

    Volume Flow

    VWAP$0.22
    OBV145.0M
    AD Line48.7B
    CMF (20d)-0.637

    Volume Metrics

    Avg Vol (20d)2.5M
    Vol Ratio0.2x(Low)
    VWMA (20d)$0.32

    Pivot Points

    R3$0.24
    R2$0.24
    R1$0.23
    Pivot Point$0.22
    S1$0.21
    S2$0.20
    S3$0.19

    Advanced Oscillators

    TSI-74.33
    Ultimate Osc21.5
    KST-695.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/AN/A$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$57,000N/A$76,000$81,000$85,000$90,000$36,000$161,000$160,000$188,000$200,000$214,000
    Gross Profit$-57,000N/A$-76,000$-81,000$-85,000$-90,000$-36,000$-161,000$-160,000$-188,000$-200,000$-214,000
    Operating Expenses$4.17M$7.91M$5.79M$2.48M$2.99M$3.53M$5.63M$3.12M$2.99M$4.15M$5.89M$5.63M
    R&D$2.92M$3.31M$3.03M$1.48M$2.14M$2.55M$3.42M$2.35M$2.00M$2.86M$4.45M$4.35M
    SG&A$1.31M$4.60M$2.72M$1.07M$937,000$954,000$1.96M$771,000$987,000$1.09M$733,000$1.28M
    Operating Income$-4,232,000$-7,914,000$-5,861,000$-2,557,000$-3,078,000$-3,533,000$-5,632,000$-3,119,000$-2,986,000$-3,950,000$-6,091,000$-5,628,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$1.33M$0$0$0$0$0$0$0$110,000$190,000$3.00M$335,000
    Income Before Tax$2.46B$1.27B$1.63B$-2,205,000$-1,868,000$-3,452,000$-5,176,000$-2,602,000$-3,096,000$-4,140,000$-9,095,000$-5,963,000
    Income Tax Expense$566.70M$293.65M$382.65M$0$0$0$0$0$0$144,724$156,188$253,586
    Net Income$1.89B$974.52M$1.24B$-2,205,000$-1,868,000$-3,452,000$-5,176,000$-2,602,000$-3,096,000$-4,140,000$-9,095,000$-5,963,000
    EBITDA$-4,171,500$-7,853,500$-5,785,000$-2,124,000$-2,993,000$-3,414,000$-5,140,000$-2,958,000$-2,826,000$-3,762,000$-5,891,000$-5,414,000
    EBIT$-4,232,000$-7,914,000$-5,861,000$-2,205,000$-3,078,000$-3,504,000$-5,176,000$-3,119,000$-2,986,000$-3,950,000$-6,091,000$-5,628,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENLV

    News

    Enlivex proposes reverse split as October 16 vote tests Enlivex stock

    Enlivex (ENLV) is holding a shareholder vote on October 16, 2026, to approve a reverse stock split with a ratio between 1-for-13 and 1-for-16. This measure is crucial for the company to regain compliance with Nasdaq's...

    ad-hoc-news.de•10/15/26•Bearish

    Enlivex moves 1-for-13 to 1-for-16 vote for Enlivex stock

    Enlivex is moving forward with a shareholder vote on October 16, 2026, for a proposed reverse stock split ranging from 1-for-13 to 1-for-16...

    ad-hoc-news.de•10/12/26•Somewhat-Bearish

    Enlivex Ltd Share Price - ENLV, RNS News, Articles, Quotes, & Charts (NASDAQ:ENLV)

    Enlivex Ltd (NASDAQ:ENLV) stock information, including its share price, news, and market data. The company is involved in late-stage clinical development of Allocetra™ for osteoarthritis and also has a strategy focused...

    Proactive financial news•10/8/26•Neutral

    Enlivex Ltd (ENLV-Q) Stock Price and News

    This page provides stock price information and recent news for Enlivex Ltd (ENLV-Q), a clinical-stage macrophage reprogramming immunotherapy company listed on NASDAQ. It includes real-time stock data, volume summaries...

    The Globe and Mail•10/6/26•Neutral

    Enlivex moves reverse split vote as Enlivex stock stays below USD 1.00

    Enlivex is seeking shareholder approval for a reverse stock split, ranging from 1-for-13 to 1-for-16, to address its stock price falling below Nasdaq's USD 1.00 minimum bid requirement. The extraordinary shareholder...

    AD HOC NEWS•10/6/26•Bearish

    ENLV Valuation and Fair Value

    P/E
    -0.1x
    P/FCF
    -0.3x
    P/B
    0.0x
    See GNG's fair value

    ENLV Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -0.3%
    ROE
    162.9%
    FCF yield
    -365.6%

    ENLV Competitors

    CompanyTicker
    Vivos Therapeutics IncVVOS
    NuCana PLCNCNA
    bioAffinity Technologies, Inc.BIAF
    Dermata Therapeutics IncDRMA
    Redhill Biopharma LtdRDHL
    Liminatus Pharma, Inc. Class A Common StockLIMN
    XTL Biopharmaceuticals Ltd ADRXTLB
    Azitra IncAZTR

    Sector: Healthcare

    ENLV Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -136.0%

    Frequently Asked Questions About ENLV

    Does ENLV pay dividends?

    Enlivex Therapeutics Ltd (ENLV) does not currently pay a regular dividend.

    What is ENLV's market cap?

    Enlivex Therapeutics Ltd (ENLV) has a market capitalization of $4.43M with a current stock price of $0.22.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In